Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Turnage

Clinical Cardiac Electrophysiology Mobile, AL Medical Doctor

NPI 1336464676 CMS profile 1309948

1700 Spring Hill Ave Ste 100, Mobile, AL 36604

Open in the dashboard

General payments

$70,878

413 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Turnage of Mobile, AL is reported in the CMS Open Payments database as having received $70,878 across 413 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18,507 49
2024 General $18,343 47
2023 General $12,875 56
2022 General $11,477 93
2021 General $6,470 70
2020 General $1,347 57
2019 General $1,857 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Turnage
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Thomas Turnage were reported at $18,507. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Thomas Turnage Clinical Cardiac Electrophysiology median Middle half National median
2019 $1,857 $2,361 $585–$8,260 $163
2020 $1,347 $993 $247–$4,351 $114
2021 $6,470 $1,185 $326–$4,739 $132
2022 $11,477 $2,073 $554–$6,789 $149
2023 $12,875 $2,568 $759–$8,159 $160
2024 $18,343 $2,557 $703–$7,403 $164
2025 $18,507 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $43,231 34 payments
  2. Biosense Webster, Inc. $15,625 55 payments
  3. Boston Scientific Corporation $4,274 58 payments
  4. Medtronic, Inc. $2,151 28 payments
  5. Abbott Laboratories $958 13 payments
  6. Medtronic Vascular, Inc. $711 13 payments
  7. Novartis Pharmaceuticals Corporation $674 41 payments
  8. Janssen Pharmaceuticals, Inc $633 47 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $559 30 payments
  10. Pfizer Inc. $323 21 payments
  11. Other $1,739 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $55,125 39 payments
  2. Food and Beverage $10,230 336 payments
  3. Travel and Lodging $5,228 35 payments
  4. Education $294 3 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $57,827 67 payments
  2. Micra $2,151 28 payments
  3. INGEVITY+ $1,226 6 payments
  4. Carto 3 System $640 8 payments
  5. XARELTO $633 47 payments
  6. LifeVest $559 30 payments
  7. ENTRESTO $450 29 payments
  8. ELIQUIS $323 21 payments
  9. Azure $294 4 payments
  10. BioMonitor $282 3 payments
  11. Other $6,338 192 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

3,719

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,055,933

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

36.5%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 818 $691,006
Xarelto Rivaroxaban Brand 242 $200,622
Entresto Sacubitril/Valsartan Brand 106 $103,684
Jardiance Empagliflozin Brand 24 $25,307
Flecainide Acetate Generic 123 $8,376
Metoprolol Succinate Generic 416 $4,700
Amiodarone Hcl Generic 298 $4,162
Carvedilol Generic 226 $2,444
Sucralfate Generic 75 $1,816
Amlodipine Besylate Generic 221 $1,565

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$200,070

Of which drugs: $355

Medicare patients

553

Average age 76

Services billed

4,072

273 women, 280 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 56%
Atrial fibrillation 56%
Heart failure 53%
Arthritis 50%
Chronic kidney disease 46%
Diabetes 42%
COPD 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 14 56 $294

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $68
  • E.R. Squibb & Sons, L.L.C. $14
$82 818 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $19
$19 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $15
$15 242 —
NURTEC ODT
  • PFIZER INC. $15
$15 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

413 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record